India CDMO Market Size, Share, Growth, and Regional Forecast, 2026 to 2033

India CDMO Market by Service Type (Contract Development Services, Contract Manufacturing Services), Product Type (Small Molecules, Biologics, Biosimilars, Vaccines, Others), Scale of Operation, Therapeutic Area, and Regional Analysis, from 2026 to 2033

ID: PMRREP34955

January 2026

198 Pages

Author : Vaishnavi Patil

Healthcare

Key Industry Highlights

India’s ability to offer cost-effective manufacturing combined with a highly skilled workforce makes it an attractive destination for global pharmaceutical companies seeking to outsource their development and manufacturing needs.
The availability of affordable labor and infrastructure allows CDMO of India to deliver high-quality products at competitive prices, driving the market growth.
The demand for generics and biosimilars is surging with the global patent expiry of several blockbuster drugs. India CDMOs, known for their strong capabilities in producing high-quality generics and biosimilars are well-positioned to meet this rising demand, further driving the India CDMO market growth.
In terms of service type, contract manufacturing services are anticipated to witness a CAGR of 14.6% through 2033 due to cost efficiency, high-quality production, and increased global outsourcing.
Based on product type, the small molecules segment is projected to showcase a CAGR of 14.1% through 2033 due to high demand for generics, and robust manufacturing infrastructure.

Key Insights	Details
India CDMO Market Size (2026E)	US$ 23.3 Bn
Market Value Forecast (2033F)	US$ 55.5 Bn
Projected Growth (CAGR 2026 to 2033)	13.2%
Historical Market Growth (CAGR 2020 to 2025)	11.6%

india-cdmo-market-size-2026–2033

Get Your CustomizationGet Your Customization

Market Dynamics

Driver - Cost Efficiency and Competitive Advantage

Cost efficiency and competitive advantage is a significant driver for the India CDMO market. India’s ability to offer low-cost manufacturing without compromising on quality has positioned it as a preferred destination for pharmaceutical outsourcing.

The country benefits from lower labor costs, reduced operational expenses, and economies of scale, making it highly competitive compared to Western countries. This cost efficiency allows Indian CDMOs to produce small molecules, APIs, finished dosage forms, and even complex biologics at a fraction of the cost.

India’s affordability, coupled with its high-quality manufacturing standards, has become a key factor in driving the expansion of the CDMO market as global pharmaceutical companies seek ways to reduce production costs. The competitive advantage India holds is further strengthened by its well-established infrastructure, skilled workforce, and expertise in meeting international regulatory standards.

Rising Demand for Generics and Biosimilars

The rising demand for generics and biosimilars is a key driver of the India CDMO Market. As patents for blockbuster drugs expire, there is an increasing need for affordable alternatives, particularly in the form of generic drugs and biosimilars. India, being the world’s largest producer of generics is well-positioned to capitalize on this trend.

India CDMOs have developed strong capabilities in manufacturing Active Pharmaceutical Ingredients (APIs) and finished dosage forms for generics, making the country a preferred outsourcing partner for global pharmaceutical companies. Additionally, the biosimilars market is experiencing rapid growth as biologic drugs face patent expirations, and the demand for cost-effective alternatives rises.

India’s expertise in biosimilars manufacturing, along with its ability to offer high-quality products at competitive prices has made Indian CDMOs crucial players in meeting the global demand for affordable therapies. This growing demand for generics and biosimilars, combined with India’s established production infrastructure continues to drive the expansion of the country’s CDMO market.

Restraints - Infrastructure and Technology Gaps in Certain Segments

One of the key restraining factors for the India CDMO market is the infrastructure and technology gaps in certain segments, particularly in the production of biologics and advanced therapeutics. While India’s pharmaceutical manufacturing infrastructure is well-established, some areas still lag in terms of state-of-the-art facilities required for producing complex biologics, cell and gene therapies, and other high-tech products.

India’s CDMO must invest significantly in upgrading their manufacturing capabilities to keep pace with global demands for biosimilars, monoclonal antibodies, and innovative biologic drugs. The lack of specialized facilities, equipment, and expertise in these cutting-edge areas can hinder India's ability to compete with more advanced markets.

As the demand for such high-complexity products increases, this gap may limit India growth potential in the biologics and advanced therapeutics sectors unless significant investments are made to address these technological challenges.

Opportunity - Rise in Outsourcing by Global Pharmaceutical Companies

The rise in outsourcing by global pharmaceutical companies presents a significant opportunity for the India CDMO Market. As pharmaceutical companies worldwide face increasing pressure to reduce costs, improve efficiency, and focus on their core competencies, outsourcing manufacturing and development services has become a strategic priority.

India, with its competitive advantages such as cost-effective production, a highly skilled workforce, and compliance with global regulatory standards has emerged as a preferred destination for outsourcing. India’s CDMOs are well-positioned to capitalize on this trend by offering end-to-end services, including drug discovery, formulation development, clinical trials, and manufacturing.

Growing demand for outsourcing, coupled with India's established infrastructure and expertise, provides Indian CDMOs with the opportunity to secure long-term partnerships with global pharmaceutical companies.

Category-wise Analysis

By Service Type Insights

Contract manufacturing services lead the India CDMO market over contract development services due to the country's established strengths in large-scale pharmaceutical manufacturing. India is a global hub for producing cost-effective Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs), supported by its extensive manufacturing infrastructure and skilled workforce.

The rising global demand for generics, biosimilars, and vaccines has further solidified the dominance of the segment as Indian CDMOs are equipped to handle high-volume production efficiently. Additionally, the cost advantages, regulatory compliance with international standards, and the presence of export-oriented facilities make contract manufacturing the preferred choice for global pharmaceutical companies.

By Product Type Insights

Small molecules dominate the product type segment in the India CDMO market due to India’s broad expertise in manufacturing Active Pharmaceutical Ingredients (APIs) and generic drugs, which are predominantly small molecules. The cost-effectiveness of producing small molecules in India, combined with its large-scale manufacturing capabilities and a well-established supply chain, makes it a preferred hub for global pharmaceutical companies.

The global demand for affordable generics has surged further boosting this segment. While biologics, biosimilars, and vaccines are growing rapidly, they require more complex infrastructure and technology, making them less dominant than small molecules.

india-cdmo-market-outlook-by-therapeutic-area-2026–2033

Request Free sampleRequest Free sample

Competitive Landscape

The competitive landscape of the India CDMO market is highly dynamic, with a mix of established industry leaders and emerging players vying for dominance in various segments such as small molecules, biologics, biosimilars, vaccines, and advanced therapeutics.

Leading players like Piramal Pharma Solutions, Syngene International, Dr. Reddy’s Laboratories, Divi’s Laboratories, Lupin Limited lead the market. These companies benefit from India’s cost-effective production capabilities and regulatory expertise, enabling them to serve global markets efficiently.

Emerging players like Biocon and Piramal Pharma Solutions are focusing on specialized areas like biologics and vaccines, carving out a niche in high-complexity segments. Competition in the market is further fueled by strategic partnerships and mergers, allowing companies to enhance their capabilities and extend their global reach.

With increasing demand for biologics, biosimilars, and advanced therapeutics, India’s CDMOs are investing in technological advancements such as continuous manufacturing and bioprocessing to stay ahead. As companies expand their international presence, particularly in North America and Europe, the competitive landscape continues to evolve, driven by innovation, cost efficiency, and growing emphasis on end-to-end services.

Key Industry Developments:

In March 2025, Raichur-based Shilpa Medicare launched a full-service hybrid CDMO, offering small molecules, large molecules, and peptides, with a strong oncology focus.
In June 2024, Lupin, a leading pharmaceutical company, announced that it had entered the contract development and manufacturing organization (CDMO) business through its newly formed subsidiary, Lupin Manufacturing Solutions (LMS). The company also revealed that Abdelaziz Toumi (Abdel) had been appointed as the Chief Executive Officer of LMS. The announcement was made on Monday, marking a strategic expansion into the growing CDMO sector.
In May 2023, Aurigene Pharmaceutical Services, a division of Indian pharmaceutical giant Dr. Reddy’s Laboratories, announced an investment of $40 million to build a state-of-the-art production facility for therapeutic proteins, antibodies, and viral vectors. The facility was located at Genome Valley, a renowned biotech park in Hyderabad, and was expected to be fully operational by the first half of 2024.

Companies Covered in India CDMO Market

Piramal Pharma Solutions
Syngene International
Dr. Reddy’s Laboratories
Divi’s Laboratories
Lupin Limited
Sun Pharmaceutical Industries Ltd.
Aurobindo Pharma
Jubilant Pharmova (Jubilant Biosys & Jubilant Generics)
Glenmark Pharmaceuticals
Capsule Pharma
Laurus Labs
Strides Pharma Science
Aurigene Pharmaceutical
Others

Frequently Asked Questions

The India CDMO market is projected to be valued at US$ 23.3 Bn in 2026.

Rising outsourcing demand, cost-competitive manufacturing, skilled workforce, strong generics/biosimilars base, expanding biologics capabilities, and global regulatory compliance.

The India market is expected to witness a CAGR of 13.2% between 2026 and 2033.

Outsourcing growth by global pharma, expansion into biologics and specialty drugs, custom API development, strategic partnerships, and advanced manufacturing technologies.

Report Attribute	Details
Historical Data/Actuals	2020 - 2025
Forecast Period	2026 - 2033
Market Analysis	Value: US$ Bn and Volume (if Available)
Country Coverage	India
Segmental Coverage	Service Type Product Type Scale of Operation Therapeutic Area Country
Competitive Analysis	Piramal Pharma Solutions Syngene International Dr. Reddy’s Laboratories Divi’s Laboratories Lupin Limited Sun Pharmaceutical Industries Ltd. Aurobindo Pharma Jubilant Pharmova (Jubilant Biosys & Jubilant Generics) Glenmark Pharmaceuticals Capsule Pharma Laurus Labs Strides Pharma Science Aurigene Pharmaceutical Others
Report Highlights	Market Forecast and Trends Competitive Intelligence & Share Analysis Growth Factors and Challenges Strategic Growth Initiatives Future Opportunities and Revenue Pockets Market Analysis Tools ?

Top-Down Market Sizing	Bottom-Up Market Sizing
Universe Definition: Total global/regional market identification	Unit Economics: Average transaction values, purchase frequencies, customer lifecycle
Segmentation Filters: Geographic, demographic, and behavioral constraints	Customer Segmentation: Detailed buyer persona development and sizing
Market Share Analysis: Competitive landscape assessment and share allocation	Penetration Analysis: Market penetration rates by segment and geography
Growth Rate Application: Historical trends and forward-looking growth assumptions	Scaling Methodology: Extrapolation techniques with confidence intervals

Interested in this report?

Request customization, ask for expert consulting, access a sample report, or simply express your interest—our team will assist you with the right insights and solutions.

Request Custom VersionRequest Custom Version

Clients

Media Citation

Get In Touch

Loading page data

Please wait a moment

Key Insights

Details

India CDMO Market Size (2026E)

US$ 23.3 Bn

Market Value Forecast (2033F)

US$ 55.5 Bn

Projected Growth (CAGR 2026 to 2033)

13.2%

Historical Market Growth (CAGR 2020 to 2025)

11.6%

Report Attribute	Details
Historical Data/Actuals	2020 - 2025
Forecast Period	2026 - 2033
Market Analysis	Value: US$ Bn and Volume (if Available)
Country Coverage	India
Segmental Coverage	Service Type Product Type Scale of Operation Therapeutic Area Country
Competitive Analysis	Piramal Pharma Solutions Syngene International Dr. Reddy’s Laboratories Divi’s Laboratories Lupin Limited Sun Pharmaceutical Industries Ltd. Aurobindo Pharma Jubilant Pharmova (Jubilant Biosys & Jubilant Generics) Glenmark Pharmaceuticals Capsule Pharma Laurus Labs Strides Pharma Science Aurigene Pharmaceutical Others
Report Highlights	Market Forecast and Trends Competitive Intelligence & Share Analysis Growth Factors and Challenges Strategic Growth Initiatives Future Opportunities and Revenue Pockets Market Analysis Tools ?

Executive Summary
1. India CDMO Market Snapshot, 2026 and 2033
2. Market Opportunity Assessment, 2026 - 2033, US$ Mn
3. Key Market Trends
4. Future Market Projections
5. Premium Market Insights
6. Industry Developments and Key Market Events
7. PMR Analysis and Recommendations
Market Overview
1. Market Scope and Definition
2. Market Dynamics
  1. Drivers
  2. Restraints
  3. Opportunity
  4. Challenges
  5. Key Trends
3. Macro-Economic Factors
  1. Global Sectorial Outlook
  2. Global GDP Growth Outlook
  3. Global Healthcare Spending Outlook
4. COVID-19 Impact Analysis
5. Forecast Factors - Relevance and Impact
Value Added Insights
1. Regulatory Landscape
2. Service Adoption Analysis
3. Value Chain Analysis
4. Key Deals and Mergers
5. PESTLE Analysis
6. Porter’s Five Force Analysis
India CDMO Market Outlook: Historical (2020 - 2025) and Forecast (2026 - 2033)
1. Key Highlights
  1. Market Size (US$ Mn) and Y-o-Y Growth
  2. Absolute $ Opportunity
2. Market Size (US$ Mn) Analysis and Forecast
  1. Historical Market Size (US$ Mn) Analysis, 2020 - 2025
  2. Current Market Size (US$ Mn) Analysis and Forecast, 2026 - 2033
3. India CDMO Market Outlook: Service Type
  1. Introduction / Key Findings
  2. Historical Market Size (US$ Mn) Analysis, By Service Type, 2020 - 2025
  3. Current Market Size (US$ Mn) Analysis and Forecast, By Service Type, 2026 - 2033
    1. Contract Development Services
    2. Preclinical Development
    3. Clinical Development
    4. Analytical and Bioanalytical Services
    5. Contract Manufacturing Services
    6. Active Pharmaceutical Ingredients (APIs) Manufacturing
    7. Finished Dosage Forms (FDFs) Manufacturing
    8. Biologics Manufacturing
    9. Packaging
4. Market Attractiveness Analysis: Service Type
5. India CDMO Market Outlook: Product Type
  1. Introduction / Key Findings
  2. Historical Market Size (US$ Mn) Analysis, By Product Type, 2020 - 2025
  3. Current Market Size (US$ Mn) Analysis and Forecast, By Product Type, 2026 - 2033
    1. Small Molecules
    2. Biologics
    3. Biosimilars
    4. Vaccines
    5. Others
6. Market Attractiveness Analysis: Product Type
7. India CDMO Market Outlook: Scale of Operation
  1. Introduction / Key Findings
  2. Historical Market Size (US$ Mn) Analysis, By Scale of Operation, 2020 - 2025
  3. Current Market Size (US$ Mn) Analysis and Forecast, By Scale of Operation, 2026 - 2033
    1. Commercial Scale
    2. Clinical Scale
8. Market Attractiveness Analysis: Scale of Operation
9. India CDMO Market Outlook: Therapeutic Area
  1. Introduction / Key Findings
  2. Historical Market Size (US$ Mn) Analysis, By Therapeutic Area, 2020 - 2025
  3. Current Market Size (US$ Mn) Analysis and Forecast, By Therapeutic Area, 2026 - 2033
    1. Oncology
    2. Cardiovascular Diseases
    3. Infectious Diseases
    4. Central Nervous System (CNS) Disorders
    5. Others
10. Market Attractiveness Analysis: Therapeutic Area
Competition Landscape
1. Market Share Analysis, 2025
2. Market Structure
  1. Competition Intensity Mapping by Market
  2. Competition Dashboard
3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  1. Piramal Pharma Solutions
    1. Overview
    2. Segments and Products
    3. Key Financials
    4. Market Developments
    5. Market Strategy
  2. Syngene International
  3. Dr. Reddy’s Laboratories
  4. Divi’s Laboratories
  5. Lupin Limited
  6. Sun Pharmaceutical Industries Ltd.
  7. Aurobindo Pharma
  8. Jubilant Pharmova (Jubilant Biosys & Jubilant Generics)
  9. Glenmark Pharmaceuticals
  10. Capsule Pharma
  11. Laurus Labs
  12. Strides Pharma Science
  13. Aurigene Pharmaceutical
Appendix
1. Research Methodology
2. Research Assumptions
3. Acronyms and Abbreviations

India CDMO Market Size, Share, Growth, and Regional Forecast, 2026 to 2033

India CDMO Market by Service Type (Contract Development Services, Contract Manufacturing Services), Product Type (Small Molecules, Biologics, Biosimilars, Vaccines, Others), Scale of Operation, Therapeutic Area, and Regional Analysis, from 2026 to 2033